Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCAT 2023 | Genetic modifiers affecting the response to hydroxyurea in children with sickle cell anemia

Miguel Brito • 27 Oct 2023
ASCAT 2023
Anemias Non-Malignant Sickle Cell Disease Hydroxyurea

Miguel Brito, PhD, Lisbon School of Health Technology, Lisbon, Portugal, discusses a pharmacogenetic study in Angolan children with sickle cell anemia which investigated whether there are genetic modifiers which affect the response of a patient to hydroxyurea treatment, and comments on how the findings may be used in future trials. This interview was recorded at the 18th Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT) 2023, held in London, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Miguel Brito

2:00
The current landscape of SCD treatment
Miguel Brito • 27 Oct 2023
1:58
Genetic variants in SCD
Miguel Brito • 27 Oct 2023

Related Videos

2:34
A national physician survey investigating the management of pulmonary thromboembolism in pregnancy
Giulia Simini • 29 Apr 2024
1:39
Considering the use of gene therapy in severe inherited thrombophilia
Beverley Hunt • 29 Apr 2024
3:01
Recent advancements in the treatment of aplastic anemia
Simona Pagliuca • 24 Apr 2024
7:15
Is alloSCT a suitable treatment option for older patients with aplastic anemia?
Antonio Risitano • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals